Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Tolerability of Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy in the Second (Contralateral) Eye of Participants With Bilateral Neovascular Age-related Macular Degeneration.

NCT07630649 is registered in ClinicalTrials.gov with Adverum Biotechnologies, Inc. as lead sponsor.

NCT NCT07630649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07630649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Tolerability of Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy in the Second (Contralateral) Eye of Participants With Bilateral Neovascular Age-related Macular Degeneration.
Lead sponsor
Adverum Biotechnologies, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2026
Completion date
June 30, 2031
Enrollment
15 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd) wet amd